Genetic screening of 120 HSPers
Genetic screening of 120 HSPers for spastin (SPG4), atlastin (SPG3A) and REEP1 (SPG31) mutations established their presence in 37% of the group tested, with 20 new mutations being found.
Hereditary spastic paraplegia (HSP) comprises a group of clinically and genetically heterogeneous diseases that affect the upper motor neurons and their axonal projections. Over 40 chromosomal loci have been identified for autosomal dominant, recessive, and X-linked HSP.
Mutations in the genes atlastin, spastin and REEP1 are estimated to account for up to 50% of autosomal-dominant HSP and currently guide the molecular diagnosis of HSP. Here, we report the mutation screening results of 120 HSP patients from North America for spastin, atlastin and REEP1, with the latter one partially reported previously.
We identified mutations in 36.7% of all tested HSP patients and describe 20 novel changes in spastin and atlastin. Our results add to a growing number of HSP disease-associated variants and confirm the high prevalence of atlastin, spastin and REEP1 mutations in the HSP patient population.
SOURCE: Clin Genet. 2010 Jul 2. [Epub ahead of print]
Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic paraplegia.
McCorquodale Iii D, Ozomaro U, Huang J, Montenegro G, Kushman A,
Citrigno L, Price J, Speziani F, Pericak-Vance MA, Züchner S, John P. Hussman
Institute for Human Genomics, University of Miami Miller School
of Medicine, Miami, FL, USA.